WHO ICTRP trial
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in…
JPRN-jRCT2031230198 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031230198 |
|---|---|
| Public title | A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND) |
| Scientific title | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) - ROCKET-ASCEND |
| Primary sponsor | Jain Neal |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Argentina;Japan;Australia;Japan;Belgium;Japan;Brazil;Japan;Canada;Japan;China;Japan;Croatia;Japan;Czech… |
| Conditions | Atopic Dermatitis;D003876 |
| Interventions | - Experimental: ARM A: Dose 1 to Dose 1 Participants from parent Rocatinlimab studies ROCKET-Ignite, ROCKET-Horizon, ROCKET-SHUTTLE, or ROCKET-ASTRO who received Dose 1 will be randomized or assigned to receive Dose 1 Every 4 Weeks (Q4W) or… |
| Registration date | Jan 7, 2023 |
| Target size | 2200 |
| Secondary IDs | NCT05882877 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: